media – Pharma & Medical Industry Insights Hub | Drugdu Insights & Updates

HOSPITALAR

Organiser：Informa Group Time：May 19 – 22, 2026 Address：Centro de Exposições Imigrantes, Rodovia dos Imigrantes, Km 1.5, São Paulo – SP Exhibition hall：São Paulo Expo Product range: Medical Equipment Zone: Hospital technical facilities and equipment; medical clinic technology and equipment; ward furniture and equipment; diagnostic and therapeutic equipment; biochemical and laboratory testing equipment; pharmaceutical products; hygiene materials; medical communication technology and equipment; comprehensive hospital information technology and services. Disabled Rehabilitation Technology Zone: Nursing equipment; nursing products; communication technology; mobile care; nursing services; medical technology; orthopedic surgical technology; outpatient care; physiotherapy; prosthetics; services; ergonomic therapy; communication technology; wheelchairs. Pharmaceutical Zone: Prescription drugs; traditional Chinese patent medicines; Western medicines; antibiotics; powder injections; infusions; tablets; ointments; capsules; various new drugs; special drugs; national protected traditional Chinese medicines; national essential medical insurance drugs; pharmaceutical raw materials; various intermediates; biochemical reagents and vaccines; various biological products. Dental Zone: Dental instruments & equipment; dental pharmaceuticals & raw ...
- Source: drugdu
- 30
- February 26, 2026
Bio-Thera Solutions’ innovative drug, Darpubayimab injection, has had its marketing authorization application accepted by the NMPA

Bio-Thera Solutions, Ltd. (SSE: 688177 ) is a global, science-driven biopharmaceutical company located in Guangzhou, China, hereinafter referred to as ” Bio-Thera ” or ” the Company ” . The Company’s marketing authorization application for its product, darpubayimab injection (hereinafter referred to as “BAT4406F” ), for the treatment of neuromyelitis optica spectrum disorder (NMOS D ) positive for anti-aquaporin 4 (AQP4) antibodies, has recently been accepted by the National Medical Products Administration. In July 2025, the interim analysis of the pivotal Phase II/III registration clinical trial of BAT4406F in neuromyelitis optica spectrum disorders (NMOSD) showed significant benefit in the experimental group, leading to a recommendation from the Independent Data Monitoring Committee (IDMC) to “terminate the trial early,” thus ending participant recruitment early. The BLA application was completed in early February 2026. NMOSD is a rare autoimmune disease characterized by high relapse and high disability rates. Its core clinical manifestations include ...
- Source: drugdu
- 35
- February 25, 2026
Dashi Pharmaceuticals licenses its migraine medication to NewCo in the United States.

On February 25th, Dashi Pharmaceutical announced an exclusive licensing agreement with Slate Medicines, a rising US biopharmaceutical company operating under the NewCo model. Dashi Pharmaceutical will exclusively license the global clinical development and commercialization rights outside of Greater China to Slate Medicines for its independently developed monoclonal antibody DS009 (SLTE-1009), which targets pituitary adenylate cyclase-activating peptide (PACAP). This drug will be used for the prevention and treatment of headaches such as migraines, and will also become the first domestically developed non-opioid biological analgesic to be exported. Slate Medicines has simultaneously completed a $130 million Series A funding round, co-led by leading US healthcare investment firms including RA Capital Management, Forbion, and Foresite Capital. The funds will primarily be used to advance the global clinical development of DS009. The company is led by CEO Gregory Oakes, who has over 30 years of industry experience. Mr. Oakes also recently served as a ...
- Source: drugdu
- 37
- February 25, 2026
United Laboratories subsidiary, UBT251 injection (a Class 1 innovative drug), achieved near-20% weight loss in Phase II clinical trials

On February 24, United Laboratories (03933) issued an announcement stating that its wholly-owned subsidiary, United Biotechnology (Zhuhai Hengqin) Co., Ltd., has independently developed a Class 1 innovative drug. UBT251 injection has completed a Phase II clinical trial in overweight/obese patients in China. This study included 205 obese or overweight patients with weight-related comorbidities. The participants had a baseline mean weight of 92.2 kg and a baseline mean BMI of 33.1 kg. The results showed that after 24 weeks of administration, the mean weight change from baseline was the highest in each of the UBT251 dose groups, reaching -19.7% (-17.5 kg), while the placebo group showed -2.0% (-1.6 kg). Furthermore, UBT251 significantly improved key secondary endpoints such as waist circumference, blood glucose, blood pressure, and blood lipids compared to placebo, with good overall safety and tolerability, and no withdrawals due to adverse events occurred. The company will initiate a Phase III clinical ...
- Source: drugdu
- 30
- February 25, 2026
Dongyangguang Pharmaceutical’s first anti-Nipah virus “lifesaving drug” has entered clinical trials, achieving a 100% mortality protection rate in animal prevention.

On February 24, Dongyangguang Pharmaceutical (06887) issued an announcement stating that the Center for Drug Evaluation of the National Medical Products Administration of China has formally accepted the company’s application for clinical trials of HEC-648 injection, a monoclonal antibody new drug targeting the Nipah virus G protein. Phase I clinical research is expected to be officially launched in 2026. Nipah virus is a highly lethal single-stranded negative-sense RNA virus, with a mortality rate ranging from 40% to 75%. Currently, Nipah virus is classified as a biosafety level 4 virus, and there are no approved targeted treatments or vaccines available.。 HEC-648 injection is a fully human monoclonal antibody targeting the Nipah virus G protein, a research achievement of the Wuhan Institute of Virology, Chinese Academy of Sciences. In animal model experiments, this drug demonstrated a 100% preventative mortality protection rate and over 80% therapeutic mortality protection rate, making it the first ...
- Source: drugdu
- 30
- February 25, 2026
34 million patients no longer rely on imported drugs

In China, the number of people suffering from attention deficit hyperactivity disorder (ADHD) has exceeded 34 million. For a long time, the clinical treatment of this group has been heavily reliant on imported drugs. With the launch of the first generic drug by Lifang Pharmaceutical, the approval of multiple dosage forms of improved new drugs by Youer Pharmaceutical, and the successful approval of innovative compound preparations by Aikebaifa, several domestically produced ADHD treatment drugs have been launched, and the reliance on imported drugs is gradually being broken. In the ADHD sector, a breakthrough battle for domestic substitution and upgrading has officially begun. 01 Market potential awaits release Attention deficit hyperactivity disorder (ADHD) is a common chronic neurodevelopmental disorder characterized by disproportionate attention deficits and hyperactivity, manifesting as poor concentration, impulsivity, hyperactivity, and learning difficulties. According to the “Pediatric Expert Consensus on Early Identification, Standardized Diagnosis and Treatment of Attention Deficit ...
- Source: drugdu
- 34
- February 25, 2026
How far can GLP-1 go in the weight loss race?

At the start of 2026, a business development (BD) deal between CSPC Pharmaceutical Group and AstraZeneca set a new record for the highest amount of foreign licensing for Chinese biopharmaceutical companies, with a potential value of over US$18.5 billion. This record-breaking business development deal has once again propelled the research and development of weight-loss drugs to a new level . According to the agreement, AstraZeneca has acquired the global exclusive rights to CSPC Pharmaceutical Group’s once-monthly injectable weight management product portfolio outside of Greater China, including one clinical-ready project SYH2082, three preclinical projects, and four new collaborative projects based on CSPC Pharmaceutical Group’s platform. It is worth mentioning that SYH2082 is a GLP1R/GIPR agonist, which means that GLP-1 will continue to be popular in the weight loss field. 01 Blood sugar reduction has been unknown for many years One day of weight loss produced a medicine king With the release ...
- Source: drugdu
- 30
- February 25, 2026
【EXPERT Q&A】How to apply for the classification and definition of medical devices?

Drugdu.com expert’s response: To ensure the authenticity and completeness of application materials, the following procedures and requirements must be followed when applying for classification determination of medical devices: I. Application Methods and Channels 1. Online Registration and Application Visit the official website of the National Institutes for Food and Drug Control (NIFDC, under the National Medical Products Administration) at https://www.nifdc.org.cn. Navigate to the “Medical Device Standards and Classification Management” section and click on the “Medical Device Classification Determination Information System.” Register an account, complete the Application Form for Classification Determination of Medical Devices, and upload other required materials. Starting from February 19, 2024, paper submissions are no longer required; the entire process is conducted electronically. 2. Paper Submission (Backup Option) If paper materials are required, print the Application Form for Classification Determination online, affix the enterprise’s paging seal to all documents, and mail them to the following addresses based on product type: Domestic Products: ...
- Source: drugdu
- 33
- February 25, 2026
Aohong Pharmaceutical | Drug registration application for Motomidyl Hydrochloride Injection accepted by CDE

Recently, the National Medical Products Administration accepted the drug registration application of Motomidate Hydrochloride Injection (Project Code: ET-26, Application Registration Category: Class 1 Chemical Drug; hereinafter referred to as “the new drug”) by Jinzhou Aohong Pharmaceutical Co., Ltd., a subsidiary of Fosun Pharma (stock code: 600196.SH; 02196.HK). The proposed indication for this application is for anesthesia induction and short-term surgical anesthesia. This new drug is a Class 1 new drug for intravenous general anesthesia and was included in the “Major New Drug Development” science and technology major project in 2014.According to the latest data from IQVIA CHPA1 , in 2024, sales of similar drugs (such as etomidate) used for anesthesia induction and short-term surgical anesthesia in mainland China (excluding Hong Kong, Macao and Taiwan) amounted to approximately RMB 4.238 billion.As a wholly-owned subsidiary of Fosun Pharma, Aohong Pharmaceutical has always regarded innovation as the core driving force for its sustainable ...
- Source: drugdu
- 40
- February 24, 2026
Hansoh Pharmaceutical’s blockbuster new drug has been approved for marketing in the European Union!

Just now, Hansoh Pharmaceutical announced that its innovative drug, Ametinib Mesylate Tablets (Chinese trade name: Ameile® , overseas trade name: Aumseqa® ) , has been officially approved by the European Commission ( EC ) for marketing in the European Union for the treatment of: First-line treatment for adult patients with advanced non-small cell lung cancer ( NSCLC ) with epidermal growth factor receptor ( EGFR ) exon 19 deletion or exon 21 ( L858R ) substitution mutation ; Treatment of adult patients with advanced EGFR T790M mutation-positive NSCLC . This approval came after the European Medicines Agency ( EMA ) Committee for Medicinal Products for Human Use ( CHMP ) issued a positive opinion. Ametinib thus becomes the first Chinese-developed EGFR-TKI drug to receive EU approval, marking another breakthrough for domestically produced targeted innovative lung cancer drugs in the European market. Ametinib mesylate tablets (Aumseqa® ) are China’s first original ...
- Source: drugdu
- 39
- February 24, 2026

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.